SavedAdd your journal

Journals / Retina-Vitreus / 2021 / Cilt: 30 - Sayı: 4

Results of Laser Photocoagulation Therapy for Retinopathy of Prematurity and Additional Treatment Requirements

Ayşegül ÇÖMEZ
Pelin ÇELEMLER
Pages
325–332
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, the requirement of additional treatment following the initial LP is greater in infants with APROP

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The objective of the study is to assess the effi ciency of treatment, additional treatment requirements and results of additional treatments in infants who underwent laser photocoagulation (LP) due to retinopathy of prematurity (ROP).
📊
Key Findings & Data:Materials and Methods: This two-center, retrospective trial evaluated the treatment results of preterm infants who underwent LP for ROP between 2013 and 2019 and who were also followed for at least 1 year following LP.
💡
Conclusion & Impact:However, the requirement of additional treatment following the initial LP is greater in infants with APROP
🔬Design:Research Article
📍Scope:2013 Verileri
⚙️Variables:Domain Parameters

Özet

Purpose: The objective of the study is to assess the effi ciency of treatment, additional treatment requirements and results of additional treatments in infants who underwent laser photocoagulation (LP) due to retinopathy of prematurity (ROP). Materials and Methods: This two-center, retrospective trial evaluated the treatment results of preterm infants who underwent LP for ROP between 2013 and 2019 and who were also followed for at least 1 year following LP. Results: Four hundred thirty-seven eyes of 225 infants were included in the study. Of the eyes treated with LP, 284 had type 1 ROP, 129 had type 2 ROP, and the remaining 24 eyes had aggressive posterior retinopathy of prematurity (APROP). After the initial LP, manifestations of ROP regressed completely in 397 (90.8%) eyes, whereas for 40 eyes (9.2%), additional treatment was required. Of these infants, 18 (45%) eyes underwent rescue intravitreal bevacizumab (IVB), while LP was applied at the posterior ridge of 16 (40%) eyes, and additional LP was applied in 6 (15%) eyes. Fourteen (58.3%) eyes with APROP and 26 (9.2%) eyes with type 1 ROP required additional treatments, and the difference between them was statistically signifi cant (p<0.001). After all follow-up and treatments, an unfavourable anatomic outcome was observed in 4 eyes (0.9%) at a corrected age of one year. Conclusion: Near-confl uent LP is an effi cient treatment, in particular for infants with type 1 and type 2 ROP. However, the requirement of additional treatment following the initial LP is greater in infants with APROP

🔖

Cite This Article

ÇÖMEZ, A., ÇELEMLER, P. (2021). Results of Laser Photocoagulation Therapy for Retinopathy of Prematurity and Additional Treatment Requirements. Retina-Vitreus, Cilt: 30 - Sayı: 4, 325–332. https://ajindex.com/articles/413565

References (8)

  1. Terry TL. Fibroblastic overgrowth of persistent tunica vasculosa lentis in infants born prematurely: ii. report of casesclinical aspects. Trans Am Ophthalmol Soc 1942;40:262-84
  2. Blencowe H, Lawn JE, Vazquez T et al. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res 2013;74 Suppl 1:35-49 3. Valentine PH, Jackson JC, Kalina RE, et al. Increased survival of low birthweight infants: impact on the incidence of retinopathy of prematurity. Pediatrics 1989; 84: 442–45 4. Mutlu FM, Sarici SU. Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. Int J Ophthalmol 2013;6:228-236. Published 2013 Apr 18. doi:10.3980/j.issn.2222-3959.2013.02.23 5. Lad EM, Hernandez-Boussard T, Morton JM, et al. Incidence of retinopathy of prematurity in the United States: 1997 through 2005. Am J Ophthalmol 2009;148:451–458
  3. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol 2001; 119:1110–1118. 5
  4. Good WV. Early treatment for retinopathy of prematurity cooperative group. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 2004;102:233–248
  5. Mintz-Hittner HA,Kennedy KA,Chuang AZ; BEAT-ROP Cooperative Group. Effi cacy of intravitreal bevacizumab for stage3+retinopathy of prematurity. N Engl J Med 2011;364:603–15.doi:10. 1056/NEJMoa1007374 9. Xu Y, Zhang Q, Kang X. Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection. Acta Ophthalmol 2013;91:e304–310
  6. Nazari H, Modarres M, Parvaresh M.M, et al. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol 2010;248:1713–1718 11. Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684-94
  7. Koç E, Baş AY, Özdek Ş, et al. Turkish Neonatal and Turkish Ophthalmology Societies consensus guideline on the retinopathy of prematurity. Turk Pediatri Ars 2018;53:151- 160
  8. International Commi